Microneedle

Tailored Individualised Therapy To Improve Clinical Outcomes

Our Centre is developing emerging, novel approaches to optimise antimicrobial use and sustain the effectiveness of these drugs in the face of increasing antimicrobial resistance (AMR) and the absence of new treatments.

We provide state-of-the-art research facilities and consolidates multidisciplinary academic excellence, clinical expertise, Imperial’s NIHR/Wellcome Clinical Research Facility (CRF), and partnerships with the NHS to support and deliver innovative research on antimicrobial optimisation and precision prescribing.

Our research includes:

  • Development of rapid diagnostic solutions for the detection of infections and genes associated with antimicrobial resistance to guide treatment decisions and optimise antimicrobial use.
  • Real-time biosensor technologies to monitor antimicrobial concentrations and disease biomarkers within the body on  microneedle or on a Point of Care devices.
  • Utilising artificial intelligence and machine learning to assist with infection detection, diagnosis, clinical decision making and providing effective guidance on antimicrobial selection, timing and concentrations to use, especially in vulnerable patient populations.

General Enquiries


CAMO Business Manager
Kerri Hill-Cawthorne
k.hill-cawthorne@imperial.ac.uk